REVIEWS

Impact of HIV infection on tuberculosis

Alimuddin Zumla, Patrick Malon, Jane Henderson, John M Grange

Centre for Infectious Diseases, University College London, Royal Free and University College Medical School, Windeyer Institute of Medical Sciences, Room G41, 46 Cleveland Street, London W1P 6DB, UK
A Zumla

Patrick Manson Ward, University College Hospital, London, UK
P Malon
J Henderson

Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, UK
J M Grange

Correspondence to:
Professor Zumla (e-mail:
a.zumla@ucl.ac.uk)

Submitted 24 March 1999
Accepted 13 July 1999

Table 1 Historical names for tuberculosis

Historical name	Clinical type of tuberculosis
Consumption (of the lungs)	Pulmonary tuberculosis
Pthisis	Pulmonary tuberculosis
Tabes pulmonalis	Pulmonary tuberculosis
Tissic	Pulmonary tuberculosis
Hectic fever	Pulmonary tuberculosis
Asthenia	Pulmonary tuberculosis
Galloping consumption	Acute progressive tuberculosis
Tabes mesenterica	Abdominal tuberculosis
Scrofula	Cervical lymphadenitis
Struma	Cervical lymphadenitis
King's evil	Cervical lymphadenitis
Pott's disease*	Spinal tuberculosis
Prosector's or Butcher's wart	Primary inoculation skin tuberculosis
Tuberculous chancre	Skin tuberculosis
Scrofuloderma	Skin tuberculosis secondary to cervical lymphadenitis
Lupus vulgaris	Chronic skin tuberculosis

*Named after Sir Percival Pott (1714–88), a surgeon at St Bartholomew's Hospital, London.

Table 2 Estimated global burden of tuberculosis (World Health Organisation, 1998)

WHO region	Total population	No infected	Annual incidence*	Annual deaths
South East Asia	1 458 000 000	704 000 000	2 800 000	1 095 000
Western Pacific	1 630 000 000	610 000 000	1 583 000	591 000
Africa	611 000 000	293 000 000	1 650 000	770 000
Americas	788 000 000	237 000 000	448 000	160 000
Europe	859 000 000	205 000 000	342 000	118 000
Eastern Mediterranean	473 000 000	161 000 000	427 000	173 000
Total	5 819 000 000	2 210 000 000	7 250 000	2 907 000

*Estimated number of new cases developing during the course of a year. Being a chronic disease, the total number of cases at a given time is much higher, around 16 million.

Keywords: HIV; AIDS; tuberculosis

Tuberculosis has been recognised since the dawn of recorded history and during the 19th century it was among the leading causes of morbidity and mortality in Europe and the USA. Some of many names that have been given to the various clinical forms of tuberculosis are listed in table 1. Starting in the latter half of the 19th century, the incidence declined significantly in the industrialised nations and by the early 1980s there was a widespread opinion that the disease had virtually been conquered. This complacent attitude was shaken in the early 1990s by the occurrence of an upsurge in the incidence of tuberculosis in New York City. It is now apparent that, far from being conquered, tuberculosis is one of the most prevalent infectious causes of human suffering and death world wide. Indeed there are more cases of tuberculosis in the world today than at any previous time in human history. Because of the relentless spread of tuberculosis throughout the world, the World Health Organisation (WHO), in 1993, took the unprecedented step of declaring tuberculosis a global emergency.¹

Global burden of tuberculosis

The global burden of tuberculosis is summarised in table 2. Each year, around seven to eight million people develop the disease. Tuberculosis causes the death of around three million people annually. The disease is responsible for 7% of all adult deaths and 25% of preventable adult deaths.² Among children, it is now an important cause of morbidity and mortality.³ The incidence and prevalence of the disease continues to rise in the developing countries while many developed countries including the USA and UK have witnessed a reversal of the downward trend that had occurred since the late 19th century.

Aetiology of tuberculosis

Most cases of human tuberculosis are caused by the human tubercle bacillus, *Mycobacterium tuberculosis*, but in countries where cattle tuberculosis still occurs human tuberculosis is also caused by *M bovis*. In addition, some cases, principally in equatorial Africa, are caused by a rather heterogeneous group of strains termed *M africanum*. Though bearing separate species names, these are really members of a single species often termed the *M tuberculosis* complex.⁴ Infection usually occurs by inhaling small droplets of cough aerosol, about 5 µm in diameter, containing tubercle bacilli. Infection

Table 3 Factors determining susceptibility to tuberculosis

Age	Those aged less than 5 years and the elderly are susceptible The 5–15 age group is relatively protected
Racial and genetic predisposition	“Herd immunity” ? HLA
Immunological factors	? Cytokine gene defects HIV infection Steroid therapy Cytotoxic drugs Post-transplant immunosuppressive therapy Congenital immunodeficiencies
Chronic medical conditions	Protein energy malnutrition Diabetes mellitus Chronic liver or renal disease Malignancies Lung damage, especially silicosis
Stress	Endocrine factors
Previous exposure to mycobacteria	BCG vaccination
Mycobacterial factors	Exposure to environmental mycobacteria Variation in strain virulence (?) Infective dose

Table 4 Global burden of HIV/AIDS, December 1998

Region	Persons infected with HIV	Prevalence (%) in 15–49 age range
Sub-Saharan Africa	22 500 000	8.0
North Africa and Middle East	210 000	0.13
South and South East Asia	6 700 000	0.69
East Asia and Pacific	560 000	0.07
Latin America	1 400 000	0.57
Caribbean	330 000	1.96
Eastern Europe and Central Asia	270 000	0.14
Western Europe	500 000	0.25
North America	890 000	0.56
Australia and New Zealand	12 000	0.1
Total	33 400 000	1.1

by *M bovis* is also acquired by drinking infected milk and the primary lesions occur in the pharynx or intestine. Rarely, infection occurs by traumatic inoculation of bacilli into the skin, particularly in butchers and others handling the carcasses of tuberculous animals.

Factors determining susceptibility to tuberculosis

Not everyone who is infected with the tubercle bacillus develops clinically evident disease. As a broad generalisation, and in the absence of obvious predisposing factors, about 5% of those infected develop primary tuberculosis within three years of infection and another 5% develop post-primary tuberculosis at any subsequent period of their lives.⁵ Many factors predispose to the development of tuberculosis and the principal ones are listed in table 3. The question of whether resistance to tuberculosis is genetically determined has generated considerable controversy. While various resistance determining genes have been delineated in the mouse, their relevance to the human situation has not been clearly established. Likewise, there is uncertainty as to whether the decline in the incidence of the disease in the developed nations over the last century is principally due to natural selection or to improving societal conditions.

Environmental factors may also affect susceptibility to progression to tuberculous disease. Thus, for example, it has been suggested that exposure to environmental mycobacteria may, depending on the nature of the exposure, have a beneficial or detrimental effect on the relevant immune responses.⁶ Age also affects susceptibility: the elderly and the very young

appear more susceptible while children between the ages of 5 years and 15 years appear relatively immune from developing tuberculosis—the “golden age group”. This age related variation in protection may be related to hormonal regulation of immune responses.⁷

Impact of the HIV/AIDS pandemic on the global burden of tuberculosis

In addition to the factors mentioned above, immunosuppression of any type is a predisposing factor for the development of tuberculosis. Since the early 1980s, HIV infection has emerged as by far the most important of all the predisposing factors.⁸ In persons co-infected with the tubercle bacillus and HIV, the overall annual risk of developing active tuberculosis rises from about 0.4% to 8%—that is, 20 times the risk.⁹ The risk depends, however, on the degree of immunosuppression—the risk of a patient with AIDS developing tuberculosis is 170 times higher than a non-immunosuppressed person. For these reasons, infection with HIV and *M tuberculosis* have been dubbed “the cursed duet”.¹⁰

At the end of 1998, over 33 million people were estimated to be infected by HIV¹¹ and the regional distribution of these is shown in table 4. Most of those infected were aged 15 to 49 years and, as shown in table 4, over 1% of this age group are HIV positive. Assuming that a third of these are co-infected with the tubercle bacillus, and that 8% of these develop active tuberculosis annually, there could be almost one million cases of HIV related tuberculosis in 1999, about 10% of the expected new cases of tuberculosis in that year. It has been estimated that tuberculosis will be the cause of 30% of the expected 2.5 million AIDS related deaths in 1999.¹¹

In addition to the high risk of developing reactivation tuberculosis, HIV positive persons can be primarily infected or reinfected by the tubercle bacillus and are at a very high risk of developing active tuberculosis.¹² The risk of such infection and reinfection tuberculosis is related to the number of source cases in the community and is therefore low in regions with a low prevalence of tuberculosis.¹³ The exact risk of tuberculosis developing after exposure of an HIV positive person to a source case is unknown owing to the difficulty in distinguishing between recent infection and reactivation. Most documented cases follow exposure of patients to source cases during hospitalisation for AIDS related illness. These patients, by implication, are profoundly immunosuppressed and their chance of progressing to overt tuberculosis after infection approaches 100%. Furthermore, the clinical course of the disease is “telescoped” down to a few months rather than years or decades.¹⁰ Such exposure in hospitals and other institutes has been responsible for a number of explosive miniepidemics, initially in New York City but subsequently in Europe.¹⁴

Prevalence and distribution of HIV related tuberculosis

The burden of HIV related tuberculosis is not evenly distributed as it is determined by the overall prevalence of infection by the tubercle bacillus and HIV in the community, in addition to the social factors that encourage a crossover between the two infections. In the USA, HIV related tuberculosis is largely restricted to socioeconomically disadvantaged communities in New York City and other large cities.¹⁵ It was the occurrence of miniepidemics of HIV associated tuberculosis in New York City in the early 1990s, and the anxieties generated in the general population, that led to an upsurge of interest and concern for this condition. In the UK, HIV related tuberculosis, while not yet a major problem, is becoming increasingly common in both immigrant and indigenous populations. Tuberculosis clinics are therefore encouraged to increase the use of HIV testing¹⁶ and HIV clinics should always keep tuberculosis high on the list of differential diagnosis in any difficult clinical case.

From the global perspective, the region most affected at the close of the millennium is sub-Saharan Africa, where 83% of all AIDS related deaths have occurred.¹⁷⁻¹⁹ However, the incidence of HIV infection is rapidly increasing in Asia, where a large percentage of the human population infected by the tubercle bacillus live.¹⁷ Within sub-Saharan Africa, East and Central African countries are particularly affected, with around one in five adults being infected with HIV.¹¹ In these countries HIV is principally transmitted heterosexually, and infection in women is as frequent as men. In Zambia at least one in four pregnant women are HIV seropositive²⁰ and, as around 50% are also infected with the tubercle bacillus, one in eight are likely to be co-infected. A recent study from Zambia indicates that HIV related tuberculosis is, after malaria, now the most important non-obstetric cause of maternal death.²¹ An increasing number of cases of tuberculosis in African children are HIV related. In Zambia, the HIV seroprevalence rate among children admitted to hospital with tuberculosis rose from 18% to 67% over an eight year period up to 1995 while over the same period, the HIV seroprevalence rate remained at a constant 10% in children admitted for surgical conditions.²²

Pathology of tuberculosis in HIV infection

The lungs of HIV positive patients dying with tuberculosis are characterised by fibrous and calcified tuberculosis lesions interspersed with newer active lesions containing tubercle bacilli.²³ The latter may be due to either reactivation of old lesions or to reinfection. The precise nature of the immune deficit that leads to an enhanced risk of tuberculosis in HIV positive patients has not been established and a range of pathological characteristics have been described. In those with relatively intact immune function and a relatively high CD4+ count, there are classical caseating granulomas characterised by mature epithelioid cells and

Table 5 Comparison of clinical features of tuberculosis in HIV infected and non-infected patients

Feature	HIV positive	HIV negative
Respiratory symptoms	+++	+++
Extrapulmonary disease	+++	+
Cavitating lung lesions	+	+++
Atypical features on chest radiography	+++	±
Negative tuberculin skin tests	++	±
Adverse drug reactions	++	±
Mortality rate	+++	±
Relapse after course of treatment	++	±

Langhans' giant cells but few or no visible bacilli. As the immune defect increases, and the CD4+ cell count declines, more diffuse lesions with abundant tissue necrosis, few or no mature epithelioid cells and numerous tubercle bacilli are encountered.²⁴⁻²⁵ Fibrotic reactions responsible for the walling off of foci of active disease are reduced in the more anergic patients, thereby encouraging local spread and widespread dissemination of disease. Cavity formation, also the result of an active, though inappropriate, immune response, is also reduced.

Clinical features of HIV related tuberculosis

The diagnosis of tuberculosis has never been easy as there is a very wide range of clinical features. The advent of HIV related tuberculosis, with many unusual presenting features, has added significantly to the diagnostic difficulties. Heightened clinical awareness remains the mainstay of diagnosis. Tuberculosis may develop at any point in the course of the HIV infection and may thus occur early in the course of HIV infection, often before any significant drop in CD4+ T cell counts occur or other clinical conditions suggestive of HIV infection or AIDS appear.

The nature, presentation, and the clinical and radiological features of tuberculosis depend on the degree of immunosuppression. In those with relatively good immunity and CD4+ cell counts, and a low viral load, the manifestations and presenting symptoms of tuberculosis are essentially similar to those in HIV negative persons. As the immunocompetence decreases, there is an increasing incidence of atypical presentations of tuberculosis, and diagnostic difficulties are posed by the rather non-specific presenting features which may be confused with those of other HIV related infections.^{3, 26-27} These atypical forms of tuberculosis include rapid progression of clinical disease after infection and a high proportion of extrapulmonary, multisite, and widely disseminated tuberculosis. The clinical features of HIV related and non-related tuberculosis are contrasted in table 5.

The most common extrapulmonary manifestations of tuberculosis are: (a) asymmetrical lymphadenopathy, (b) pericarditis, (c) pleurisy, and (d) bone and skin. For reasons that are not clear, involvement of the central nervous and genitourinary systems is, relative to the industrialised countries, uncommon in Africa.²⁸ More generalised dissemination of disease may result in numerous minute lesions throughout

the body. This condition, termed cryptogenic disseminated tuberculosis, may be very difficult to diagnose during life. Many unsuspected cases are therefore diagnosed at necropsy and pose serious risks to the pathologist. Tuberculin tests may be negative, particularly in the more severely immunosuppressed, although the extent of induration is not closely related to the CD4+ lymphocyte count and is thus an independent marker of immune competence.²⁹ Blood cultures are positive in between a third and a half of patients with disseminated HIV related tuberculosis.³⁰

A high proportion of African patients with AIDS develop severe wasting and is thus known locally as "slim disease". Many such patients have chronic diarrhoea and the condition was thus thought to be caused by enteropathy but in one study in Africa almost half the AIDS patients died with "slim disease" and almost half of these were found to have disseminated tuberculosis on necropsy, compared with just over a quarter of those dying without such wasting.³¹

HIV related tuberculosis in children

The clinical differences in the disease between HIV positive and HIV negative children are not as striking as in adults.²² In Africa, a large proportion of paediatric clinic attendances and hospital admissions are for pulmonary diseases and distinguishing tuberculosis from the other causes is never easy and is usually based on clinical features, tuberculin testing, and a history of exposure to a source case. Laboratory investigations are often unhelpful as lesions are usually closed and sputum, even when it can be obtained, is almost always negative for acid-fast bacilli on microscopy. Even when the most advanced diagnostic facilities are available, the diagnosis can only be confirmed by culture in about half the cases.³² Positive cultures may be obtained from unusual sites: in a study in South Africa six of 14 HIV infected children with culture positive tuberculosis had otorrhoea and ear swabs were the source of the positive cultures in three such cases.³³

Additional diagnostic difficulties are experienced in HIV positive children as the common diagnostic criteria such as chronic cough, weight loss, and failure to thrive may also be the result of other HIV related pulmonary infections such as *Pneumocystis carinii* pneumonia and disease due to environmental mycobacteria, especially members of the *M avium* complex.³⁴ Likewise, the radiological characteristics of these other infections may be indistinguishable from those of tuberculosis. Thus, in the developing countries, misdiagnosis is common, rendering it difficult to assess the magnitude of the problem of HIV related tuberculosis in children. An idea of the true risk of tuberculosis in HIV infected children may be obtained from necropsy studies. One such study in West Africa suggested a low risk³⁵ but necropsies performed on HIV positive children in Bulawayo, Zimbabwe, established a diagnosis of tuberculosis in six out of 122 children (5%).³⁶ A large necropsy study of children

dying from respiratory diseases is currently underway in Zambia.

Diagnosis of tuberculosis

In view of the problems encountered in the clinical diagnosis of tuberculosis, a huge amount of effort has been placed in the development of rapid and sensitive diagnostic tests but serious problems have been encountered. Traditionally, diagnosis has been made by the microscopical demonstration of acid-fast bacilli in biological specimens and by in vitro cultivation of tubercle bacilli. Neither approach is completely satisfactory and attention has recently turned to molecular methods of diagnosis.

MICROSCOPY

This is principally applied to sputum but other specimens include bronchoalveolar lavage fluid, gastric washings, laryngeal swabs, cerebrospinal fluid, pleural, pericardial and peritoneal effusions, fine needle lymph node aspirates, bone marrow aspirates, and tissue biopsies. Ideally, three sputum specimens collected on successive days should be examined but, particularly in resource poor countries, this encourages non-compliance and overburdens the laboratory.⁴ Children rarely produce sputum: only 5% of cases of childhood pulmonary tuberculosis are smear positive. Gastric aspirates are more likely to be positive but laryngeal swabbing is distressing to the child, exposes the operator to risk of infection, and gives a low diagnostic yield.

Microscopy of sputum is rapid, permitting a presumptive diagnosis to be made on the patient's first visit to the clinic, but it is insensitive as there must be at least 5000 organisms in 1 ml of sputum to render their detection likely. Microscopy does not permit the distinction between tubercle bacilli and environmental mycobacteria, but this is not a major problem in regions where tuberculosis is common. As mentioned above, patients with HIV related tuberculosis, particularly those with more profound immunosuppression and no cavity formation, are more likely to be sputum negative than those with typical cavitating post-primary disease.

CULTURE

By facilitating an identification at species level, isolation of *M tuberculosis* in culture provides a definitive diagnosis. The traditional method of inoculating solid media such as the egg based Löwenstein-Jensen medium is sensitive but slow as growth may not be visible until after three or more weeks' incubation. More rapid results are obtained by the use of commercially available culture systems based on the liberation of radiolabelled carbon dioxide (CO₂) or changes in the colour or fluorescence of dyes due to the liberation of CO₂ or consumption of oxygen.⁴

SEROLOGICAL TESTS

There have been numerous attempts to develop serological tests for tuberculosis and a few are commercially available but serious

problems of specificity and sensitivity have been encountered. Owing to compromised immune responses, sensitivity is even lower in patients with HIV related tuberculosis.³⁷

MOLECULAR METHODS

In view of the problems encountered with the traditional microbiological methods, the application of nucleic acid (DNA and RNA) amplification techniques—the polymerase chain reaction (PCR) and the ligase chain reaction (LCR)—is the subject of intense research activity. As a result, a number of rapid, sensitive, and specific test kits are commercially available.³⁸ Problems arise as a result of the presence of inhibiting substances in some clinical specimens which reduce sensitivity, especially in smear negative sputum specimens, and the unexplained occurrence of a few “false” positive results.⁴ Another problem is cross contamination, although this is minimised by closed, isothermal, systems based on the amplification of specific messenger RNA which has a short half life.

Molecular techniques also permit the rapid identification of mycobacteria other than *M. tuberculosis* and the determination of rifampicin resistance by detection of mutations in the *RpoB* gene responsible for resistance.³⁹

A further application of molecular technology is the “fingerprinting” of isolates, or PCR products, of *M. tuberculosis*. Such techniques have been used to investigate miniepidemics of HIV related tuberculosis and to differentiate between reactivation of old lesions and recent infection. It has thus been shown that, particularly among HIV positive persons, reinfection occurs much more frequently than previously expected.⁴⁰ At the present time, the cost of nucleic based technology rather than technical problems precludes its use in resource poor countries.

CHEST RADIOGRAPHY

The radiological appearance of pulmonary tuberculosis in both HIV negative and positive is very variable, but more so in the latter.^{41–42} Classical chest radiograph appearances of tuberculosis are seen in approximately one third of HIV infected patients while the others show a range of atypical appearances. Radiological studies of adult Zairean and Zambian patients with HIV related tuberculosis show a significantly increased incidence of lymphadenopathy, pleural effusions, parenchymal changes, consolidation and miliary disease, but significantly less cavitary disease and atelectasis.⁴² Intrathoracic lymphadenopathy, uncommon in HIV uninfected adults with post-primary tuberculosis, is evident in 25%–50% in HIV infected adults with pulmonary tuberculosis.⁴³ The factors determining the radiological appearance of tuberculosis in HIV positive patients are poorly understood. Contrary to previous opinion, the ability to form cavities and fibrotic changes do not appear to be directly related to the CD4+ cell counts. The occurrence of atypical radiological manifestations of HIV related pulmonary tuberculosis has implications for the accurate diagnosis

of the disease and a high degree of clinical suspicion is therefore required.

Treatment of HIV related tuberculosis

The standard WHO recommended antituberculosis regimen is a six month course of rifampicin and isoniazid, with the addition of pyrazinamide, together with ethambutol (or streptomycin) during the first two months of treatment. Supplementation with daily pyridoxine (vitamin B6) to prevent isoniazid induced neuropathy is now routine.

Antituberculous regimens based on drugs other than rifampicin, or the use of rifampicin only during the first two months, have been used on the grounds that they are cheaper. The cost difference is now not so great and, in terms of relapse rates and duration of treatment, the rifampicin based regimens are ultimately much more cost effective.

Thiacetazone based regimens, though cheap, cause an unacceptably high incidence of severe toxic reactions in HIV infected persons and they should be universally abandoned.

There is little or no difference in relapse rate between HIV infected and uninfected patients when rifampicin based short course treatment is used. Thus, in the absence of drug resistance, the standard short course described above is recommended.⁴⁴ Nevertheless, some physicians continue treatment for nine months to further reduce the risk of relapse.^{45–46} Unfortunately, as outlined below, many patients die of other HIV related complications during or after completion of antituberculosis treatment. In one study, extending rifampicin based treatment from six to 12 months reduced the relapse rate but did not improve survival.⁴⁷

In addition, owing to a range of human factors, including negative perception of the disease, its treatment and outcome and the stigmatising nature of the diagnosis, HIV positive patients in some regions are less likely than seronegative patients to complete treatment.⁴⁸ Thus it is essential to adopt strategies of directly observed therapy (DOT) in order to ensure completion of treatment.⁴⁴ This strategy may also help to limit the emergence of drug resistant tuberculosis but, in several African countries, even the establishment of national tuberculosis programmes employing DOT based strategies, is failing to stem the rising tide of tuberculosis. In Botswana, for example, the incidence of tuberculosis rose by 120% between 1989 and 1996, paralleling that of the prevalence of HIV infection, despite a decade of such strategies and a low prevalence of drug resistance.⁴⁹

Adverse effects of antituberculosis chemotherapy

Adverse effects of first line antituberculosis drugs occur in both HIV infected and uninfected patients and the patient should be monitored carefully for these. Side effects of antituberculosis drugs are comparatively more frequent in the HIV infected tuberculosis patients and very severe and even fatal reactions have been observed in several studies. The most serious problems are encountered

Table 6 Drug interactions with rifampicin*

Effect of drug opposed by rifampicin	
Protease inhibitors	Non-nucleoside reverse transcriptase inhibitors
Azathioprine	Cyclosporin
Diazepam	Digoxin
Glucocorticoids	Haloperidol
Imidazole antifungals	Oral contraceptives
Opioids	Phenytoin
Propanolol	Quinidine
Theophylline	Tolbutamide
Warfarin	
Effects of rifampicin potentiated	Cotrimoxazole

*Data from Grange *et al* updated.⁵²

with thiacetazone, notably dermal reactions including exfoliative dermatitis and the frequently fatal Stevens-Johnson syndrome. In one study of adults from Kenya, thiacetazone toxicity was 18 times more frequent in HIV positive, than in HIV negative, patients and the risk was directly related to the degree of immunosuppression, suggesting an immunological basis.⁵⁰ A study of Zambian children demonstrated severe fatal reactions to thiacetazone and highlighted the advantages of thiacetazone-free regimens.⁵¹ Accordingly, as mentioned above, regimens containing thiacetazone should no longer be used.

Antituberculous drug interactions

A number of interactions between antituberculosis agents and other drugs have been described.⁵² Most interactions are associated with rifampicin due to its ability to induce cytochrome CYP450 enzymes in the liver which affect the metabolism of many other drugs (table 6). In addition to affecting the metabolism of antifungals and other drugs that HIV positive patients may require, serious interactions may occur between rifampicin and antiretroviral drugs (protease inhibitors and non-nucleoside reverse transcriptase inhibitors). The recommended practice was to stop antiretroviral treatment so that rifampicin could be used to treat tuberculosis but the current recommendation is to replace rifampicin by rifabutin, a much less powerful inducer of cytochrome enzymes, and to start or continue with the antiretroviral drugs.⁴⁶ Even if rifabutin is substituted for rifampicin, care should be exercised in the use of the protease inhibitor saquinavir and the non-nucleoside reverse transcriptase inhibitors as rifabutin decreases their levels, with the risk of selection of drug resistant viruses.⁸ Another problem encountered with the simultaneous administration of antiretrovirals and antituberculosis chemotherapy is the temporary exacerbation of the symptoms and signs of tuberculosis—the so-called paradoxical reactions.⁵³ These, which have been ascribed to hypersensitivity reactions to antigen released by bacilli killed by the chemotherapy, manifest as fever, enlargement of affected lymph nodes, and a worsening of the radiological appearance. They are occasionally encountered in HIV seronegative patients but their incidence is higher in HIV seropositive patients, particularly those given antiretroviral drugs, probably as a result of improving immune responsiveness. These reactions are not indicative of treatment failure

and usually subside spontaneously. Treatment should not be modified but short courses of steroids may be required for severe paradoxical reactions.⁴⁶

Mortality in patients with HIV related tuberculosis

There is considerable evidence that HIV seropositive patients with tuberculosis are at a higher risk of dying than their HIV seronegative counterparts during or after treatment for tuberculosis, with death usually being caused by complications of HIV infection rather than to tuberculosis itself.^{54–55} A study in Malawi showed the former were 2.5 times as likely to die during treatment, with half the deaths occurring during the first month of treatment.⁵⁶ The risks of dying for those with smear negative and extrapulmonary tuberculosis were, respectively, 3.9 and 2.6 higher than those with sputum positive disease, probably as the former tend to be associated with more profound immunosuppression. The risk of death is related to the antituberculosis regimen used. In Uganda, the risk of death within a year of starting treatment was 60% higher in patients treated with streptomycin, thiacetazone, and isoniazid than in those receiving rifampicin-based regimens.⁵⁷ This may be attributable to the prevention of other opportunistic AIDS related infections by the broad antimicrobial activity of rifampicin. Nevertheless, it is important to diagnose and treat other opportunistic infections that occur during the course of antituberculosis treatment.⁴⁴

The reason for the high mortality associated with the onset of HIV related tuberculosis, even when treated vigorously, is not clear. It may be the result of a poorly understood synergy between the two infections which accelerates the decline in immune competence and also greatly increases the viral load.⁵⁸ This synergy may be due to an induction of HIV replication by cytokines, including tumour necrosis factor- α , induced by the tuberculous process. In addition, tuberculosis *per se* is associated with a reduction in the CD4+ lymphocyte count which may be additive to that resulting from the HIV infection. In view of the deleterious effect of tuberculosis on the course of HIV infection, all forms of tuberculosis are classified as AIDS defining conditions.⁵⁹

Drug resistant tuberculosis

A further complicating factor is the occurrence of drug resistant tuberculosis. Many of the cases in these outbreaks reported in New York City were multidrug resistant which, by definition, are resistant to rifampicin and isoniazid with or without resistance to other drugs.⁶⁰ This was the result of poor medical care previously received by the patients who were mostly from socioeconomically underprivileged sectors of the community. HIV infection *per se* is not a predisposing factor for the development of multidrug resistance and, in many other parts of the world, such an association does not occur.^{61–62} Tests for drug susceptibility are often not possible in developing countries but they

should certainly be performed in the industrialised nations.⁴⁴

Infection control in health care settings

As several miniepidemics of HIV related tuberculosis, including multidrug resistant forms, have followed exposure to source cases within hospitals and clinics, well defined policies for the prevention of transmission of tuberculosis within such institutions, including isolation of known and suspect infectious patients, are essential.⁶³

Prophylaxis against tuberculosis in co-infected persons

In view of the very high risk of a co-infected person developing active tuberculosis, and the adverse effect of this disease on the immune status and survival of the patient, there is a very good theoretical case for provision of prophylactic treatment for those at risk. In practice, serious problems have been encountered in diagnosing dual infection, ruling out active tuberculosis, and ensuring compliance with treatment without breach of confidence or enhancement of stigma.^{63 64}

In the initial studies, a 12 month course of isoniazid was found to lower the incidence of tuberculosis in co-infected persons.^{65 66} Subsequently, shorter combination regimens have also been shown to be effective. These include a three month course of a rifamycin (rifampicin or rifabutin) plus isoniazid and a two month course of a rifamycin plus pyrazinamide.^{46 67-69} A study in Zambia revealed that the two month combination regimens or six months of isoniazid, administered twice weekly, reduced the incidence of tuberculosis by about 40% compared with a placebo group, although the overall mortality due to all causes was not reduced.⁷⁰ Prevention was more effective in those with relatively limited immunosuppression (positive tuberculin tests, high lymphocyte counts, and high haemoglobin concentrations). By 18 months, the incidence of tuberculosis in those who had received prophylaxis was similar to that in the placebo group; probably due to reinfection and thus indicating the need to consider repeated courses or, perhaps, lifelong prophylactic treatment.

HIV infection and tuberculosis of bovine origin

Tuberculosis due to *M bovis* is transmitted from cattle to humans and, occasionally from humans to cattle, but the evidence for human to human transmission is weak and anecdotal.⁷¹ This has led to the concept, never formally proved, that *M bovis* is less virulent for humans than *M tuberculosis*. There have, however, been reports of a high incidence of HIV related tuberculosis due to *M bovis* among Mexicans arriving in the USA⁷² and also a report of a miniepidemic resulting from exposure in an AIDS unit to a patient infected with a tubercle bacillus closely resembling *M bovis*.¹⁴ If confirmed, an increased susceptibility of HIV infected persons to this form of tuberculosis could generate a serious human health prob-

lem in regions, including many African countries, where the prevalence of HIV infection is high and where cattle tuberculosis has not been eradicated.⁷³

BCG vaccination in HIV infected persons

There is a risk that vaccination with Bacille Calmette-Guérin (BCG), a living attenuated vaccine, will cause infectious complications in HIV positive persons.⁷⁴ There is a small increase in the incidence of adverse effects of BCG in the children of HIV infected women, but most such effects are mild.⁷⁵ In one study, complications occurred in nine of 68 HIV infected children three to 35 months after neonatal BCG vaccination. Regional lymphadenopathy with or without fistula formation occurred in seven and systemic disease in two.⁷⁶ Accordingly, the safety of BCG vaccination in regions with a high incidence of HIV infection requires consideration. The WHO has advised that, while persons known to be HIV positive should never be given BCG, routine immunisation of infants should nevertheless continue in areas with a high incidence of tuberculosis and HIV infection.⁷⁷ In the UK it is recommended infants born to mothers known or suspected to be HIV positive that should not receive BCG unless they are subsequently shown to be HIV negative.⁷⁸

Conclusions

The emergence of the HIV pandemic over the last two decades has had a devastating effect on tuberculosis world wide, but principally in sub-Saharan Africa. In 1999, around 10% of all cases of tuberculosis will be HIV related, rising to over 20% in Africa. In addition, 30% of the expected 2.5 million AIDS related deaths in 1999 will be due to tuberculosis. It is expected that the problem will likewise become extensive in Asia over the next decade. Many African countries report that their health care facilities are overwhelmed by the additional burden of HIV related tuberculosis and urgent action is therefore required to stem this epidemic before it becomes totally unmanageable, with devastating human and economic consequences which will be felt throughout the world.

The difficulties in diagnosis posed by the varied clinical manifestations of tuberculosis and the particularly high incidence of atypical presentations in HIV positive patients, together with the problems of management, must be borne in mind by the practising physician. As the incidence of tuberculosis, especially of cases that are HIV related, continues to escalate world wide, physicians and pathologists must keep tuberculosis high on the list of differential diagnoses in any problematic clinical case.

1 World Health Organisation. *TB—a global emergency*. Geneva: WHO, 1994.

2 Murray CJ, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. *Bulletin of the International Union of Tuberculosis and Lung Disease* 1990;65: 6–24.

3 Chintu C, Zumla A. Pediatric tuberculosis and the HIV epidemic. In: Zumla A, Johnson M, Miller RF, eds. *AIDS and respiratory medicine*. London: Chapman and Hall, 1997: 153–63.

- 4 Collins CH, Grange JM, Yates MD. *Tuberculosis bacteriology. Organization and practice*. 2nd Ed. Oxford: Butterworth Heinemann, 1997.
- 5 Ravighione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA* 1995;273:220–6.
- 6 Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. *Lancet* 1995;346:1339–45.
- 7 Rook GAW, Hernandez-Pando R, Baker R, et al. Human and murine tuberculosis as models for immuno-endocrine interactions. In: Rook GAW, Lightman S, eds. *Steroid hormones and the T cell cytokine profile*. London: Springer, 1997: 193–220.
- 8 Havlir DV, Barnes PE. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1999;340: 367–73.
- 9 Dolin PJ, Ravighione MC, Kochi A. Global tuberculosis incidence and mortality during 1990–2000. *Bull World Health Organ* 1994;72:213–20.
- 10 Chretien J. Tuberculosis and HIV. The cursed duet. *Bull Int Union Tuberc Lung Dis* 1990;65:25–8.
- 11 UNAIDS. *AIDS epidemic update, December 1998*. Geneva: World Health Organisation, 1998.
- 12 Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City—an analysis by DNA fingerprinting and conventional epidemiologic methods. *N Engl J Med* 1994;330:1710–16.
- 13 Leitch AG, Rubilar M, Watt B, et al. Why disease due to *Mycobacterium tuberculosis* is less common than expected in HIV-positive patients in Edinburgh. *Respir Med* 1995;89: 495–7.
- 14 Bouvet E, Casalino E, Mendoza-Sassi G, et al. A nosocomial outbreak of multidrug-resistant *Mycobacterium bovis* among HIV-infected patients. A case-control study. *AIDS* 1993;7:1453–60.
- 15 Coker R. Lessons from New York's tuberculosis epidemic. *BMJ* 1998;317:616.
- 16 Coker R, Miller R. HIV associated tuberculosis. *BMJ* 1997; 314:1847.
- 17 World Health Organisation. *The world health report 1998*. Geneva: WHO, 1998.
- 18 Ustianowski A, Mwaba P, Zumla A. Tuberculosis and HIV—perspectives from sub-Saharan Africa. In: Porter JDH, Grange JM, eds. *Tuberculosis—an interdisciplinary perspective*. London: Imperial College Press, 1999.
- 19 Blinkhoff P, Bukanga E, Syamalewve B, et al. *Under the mupundu tree*. Strategies for Hope Series No 14. London: Actionaid, 1999.
- 20 Fylkesnes K, Musonda RM, Kasumba K, et al. The HIV epidemic in Zambia: socio-demographic prevalence patterns and indications of trends among childbearing women. *AIDS* 1997;11:339–45.
- 21 Ahmed Y, Mwaba P, Grange JM, et al. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. *International Journal of Tuberculosis and Lung Disease* 1999;3:1–6.
- 22 Chintu C, Zumla A. Childhood tuberculosis and infection with the human immunodeficiency virus. *J R Coll Phys Lond* 1995;29:92–94.
- 23 Lucas S, Nelson AM. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Bloom BR, ed. *Tuberculosis: pathogenesis, protection and control*. Washington: ASM Press, 1994: 503–13.
- 24 Lucas S, Wamukota W. HIV and the local African population. In: Pounder RE, Chiodini PL, eds. *Advanced medicine*. London: Balliere-Tindall, 1987: 102–11.
- 25 Nambuya A, Sewankambo N, Mugerwa J, et al. Tuberculous lymphadenitis associated with human immunodeficiency virus infection in Uganda. *J Clin Pathol* 1988;41:93–6.
- 26 Huebner RE, Castro KG. The changing face of tuberculosis. *Ann Rev Med* 1995;46:47–55.
- 27 Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. *Am J Resp Crit Care Med* 1995;151:129–34.
- 28 Harries AD. Tuberculosis in HIV-infected persons with special emphasis on sub-Saharan Africa. *J Infect* 1998;37:205–9.
- 29 Diagbouga S, Fumoux F, Ledru E, et al. Lack of direct correlation between CD4+ lymphocyte counts and induration sizes of the tuberculin skin test in human immunodeficiency virus type 1 seropositive patients. *International Journal of Tuberculosis and Lung Disease* 1998;2:317–23.
- 30 Di Leonardo M, Isola NC, Ambroggi M, et al. *Mycobacteria* in HIV-infected patients in Buenos Aires. *Tuber Lung Dis* 1995;76:185–9.
- 31 Lucas SB, de Cock KM, Hounnou A, et al. Slim disease in Africa: the contribution of tuberculosis. *BMJ* 1994;308: 1531–3.
- 32 Starke JR, Taylor-Watts RT. Tuberculosis in the paediatric population in Houston, Texas. *Pediatrics* 1989;84:28–35.
- 33 Schaaf HS, Geldenduyts A, Gie RP, et al. Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. *Pediatr Infect Dis J* 1998;17:599–604.
- 34 Donald PR. Clinical manifestations of tuberculosis. In: Donald PR, Fourie B, Grange JM, eds. *Tuberculosis in childhood*. Pretoria: JL van Schaik, 1999: 61–102.
- 35 Lucas SB, Peacock CS, Hounnou A, et al. Disease in children infected with HIV in Abidjan, Cote-d'Ivoire. *BMJ* 1996;312:335–8.
- 36 Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. *Arch Dis Child* 1997;76:124–8.
- 37 Wilkins EGL. Antibody detection in tuberculosis. In: Davies PDO, ed. *Clinical tuberculosis*. London: Chapman and Hall, 1998: 81–96.
- 38 Tan MF, Ng WC, Chan SH, et al. Comparative usefulness of PCR in the detection of *Mycobacterium tuberculosis* indeterminate clinical specimens. *J Med Microbiol* 1997;46:164–9.
- 39 Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampicin resistance in *Mycobacterium tuberculosis*—a molecular story. *J Med Microbiol* 1998;47: 189–96.
- 40 van Embden JDA, Cave MD, Crawford JT. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting: recommendations for a standardised methodology. *J Clin Microbiol* 1993;31:406–9.
- 41 Daley CL. The typically “atypical” radiographic presentation of tuberculosis in advanced HIV disease. *Tuber Lung Dis* 1995;76:475–6.
- 42 Tshibwabwa-Tumba E, Mwinga A, Pobee JOM, et al. Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three central African hospitals. *Clin Radiol* 1997;52:837–41.
- 43 Saks AM, Posner R. Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. *Clin Radiol* 1992;46:387–90.
- 44 Scientific Statement. Treatment regimens in HIV-infected tuberculosis patients. An official statement of the International Union Against Tuberculosis and Lung Disease. *International Journal of Tuberculosis and Lung Disease* 1998;2: 175–8.
- 45 Murray JF. Tuberculosis and HIV infection: a global perspective. *Respiration* 1998;65:335–42.
- 46 Centers for Disease Control. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. *MMWR Morb Mortal Wkly Rep* 1998;47(RR-20):1–58.
- 47 Perriens JH, St Louis ME, Mukudi MB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. *N Engl J Med* 1995;32:779–84.
- 48 Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. *Lancet* 1995;345:607–10.
- 49 Kenyon TA, Mwasekaga MJ, Huebner R, et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. *International Journal of Tuberculosis and Lung Disease* 1999;3: 4–11.
- 50 Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. *Lancet* 1991;337:627–30.
- 51 Luo C, Chintu C, Bhatt G, et al. HIV-infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thiacetazone-free regimen. *Tuber Lung Dis* 1994;75:111–15.
- 52 Grange JM, Winstanley PA, Davies PDO. Clinically significant drug interactions with antituberculosis agents. *Drug Saf* 1994;11:242–51.
- 53 Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. *Am J Respir Crit Care Med* 1998;158: 157–61.
- 54 Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with “standard” chemotherapy in Kinshasa, Zaire. *Am Rev Respir Dis* 1991;144:750–5.
- 55 van den Broek J, Mfinanga S, Moshiri C, et al. Impact of human immunodeficiency virus on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. *International Journal of Tuberculosis and Lung Disease* 1998;2:547–52.
- 56 Harries AD, Nyangulu DS, Kang'ombe C, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus status in Zomba Hospital, Malawi. *Trans R Soc Trop Med Hyg* 1998;92:343–7.
- 57 Okwera A, Whalen C, Bykewaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. *Lancet* 1994;334:1323–8.
- 58 Goletti D, Weissman D, Jackson RW, et al. Effect of *Mycobacterium tuberculosis* on HIV replication: role of immune activation. *J Immunol* 1996;157:1271–6.
- 59 Centers for Disease Control. The 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Morb Mortal Wkly Rep* 1993;41(17):1–19.
- 60 Kochi A, Varelzdis B, Styblo K. Multidrug-resistant tuberculosis and its control. *Res Microbiol* 1993;144:104–10.
- 61 Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug resistant tuberculosis. *Am J Respir Crit Care Med* 1996;154:1478–83.
- 62 Mitike G, Kebede D, Yenneneh H. HIV infection and antituberculosis drug resistance among pulmonary tuberculosis patients in Harar Tuberculosis Centre, Ethiopia. *East Afr Med J* 1997;74:154–7.
- 63 International Union of Tuberculosis and Lung Disease/World Health Organisation. Statement: tuberculosis preventive therapy in HIV-infected individuals. *Tuber Lung Dis* 1994;75:96–8.

- 64 O'Brien RJ, Perriens JH. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. *AIDS* 1995;9:665-73.
- 65 Pape JW, Jean SS, Ho JL, *et al.* Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. *Lancet* 1993;342:268-72.
- 66 Hawken MP, Meme HK, Elliott LC, *et al.* Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: results of a randomised controlled trial. *AIDS* 1997;11:875-82.
- 67 Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. *BMJ* 1998;317:625-9.
- 68 Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. *Ann Intern Med* 1998;129:779-86.
- 69 Halsey NA, Coberly JS, Desormeaux J, *et al.* Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. *Lancet* 1998;351:786-92.
- 70 Mwinga A, Hosp M, Godfrey-Faussett P, *et al.* Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. *AIDS* 1998;12:2447-57.
- 71 Grange JM, Collins CH. Tuberculosis and the cow. *Journal of the Royal Society of Health* 1997;117:119-22.
- 72 Dankner WM, Waacke NJ, Essey MA, *et al.* Mycobacterium bovis infections in San Diego: a clinicoepidemiological study of 73 patients and a historical review of a forgotten pathogen. *Medicine* 1993;72:11-37.
- 73 Daborn CJ, Grange JM, Kazwala RR. The bovine tuberculosis cycle—an African perspective. *J Appl Bacteriol (Symposium Supplement)* 1996;81:27-32S.
- 74 Talbot EA, Perkins MD, Silva SFM, *et al.* Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. *Clin Inf Dis* 1997;24:1139-46.
- 75 O'Brien KL, Ruff AJ, Louis MA, *et al.* Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. *Pediatrics* 1995;95:414-8.
- 76 Besnard M, Sauvion S, Offredo C, *et al.* Bacillus Calmette-Guérin infection after vaccination of human immunodeficiency virus-infected children. *Pediatr Infect Dis* 1993;12:993-7.
- 77 World Health Organisation. HIV and routine childhood immunization. *Wkly Epidemiol Rec* 1987;62:297-9.
- 78 Report. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Guidelines on the management of tuberculosis and HIV infections in the United Kingdom. *BMJ* 1992;304:1231-3.

Multiple choice questions

Q1. The following statements are true:

- (A) In patients co-infected with tuberculosis and HIV the overall annual risk of developing active tuberculosis rises on average twofold.
- (B) In sub-Saharan Africa, there are twice as many men as women infected with HIV.
- (C) In Zambia, HIV is the second commonest cause of non-obstetric maternal death.
- (D) AIDS patients with active pulmonary tuberculosis predominantly exhibit cavitating granulomatous lung lesions.
- (E) Mortality associated with tuberculosis is similar in patients with HIV and in those without HIV.

Q2. In patients disseminated tuberculosis co-infected with HIV:

- (A) Tuberculin skin tests may be negative.
- (B) Blood cultures for mycobacteria are rarely positive.
- (C) Pericarditis is a common extrapulmonary manifestation.
- (D) Central nervous system involvement is invariably seen.
- (E) Patients are less prone to weight loss than patients with non-HIV associated tuberculosis.

Q3. With regards to treatment for tuberculosis in HIV infected patients the following are true:

- (A) Addition of pyridoxine to antituberculosis regimens prevents ethambutol induced neuropathy.

- (B) Extending antituberculosis treatment from six to 12 months results in a lower relapse rate and an improved survival rate.
- (C) Rifampicin interacts with antiretrovirals by inhibiting the cytochrome CYP450 enzyme thus reducing the levels of the antiretroviral drugs.
- (D) Current recommendations state that antiretrovirals should be continued while a patient is being treated for tuberculosis.
- (E) HIV positive patients with tuberculosis experience more hypersensitivity reactions than HIV negative patients with tuberculosis.

Q4. The following statements with regards to tuberculosis are true:

- (A) HIV positive patients are more likely to be "smear positive" than HIV negative patients.
- (B) Identification of acid fast bacilli on microscopy enables the diagnosis of tuberculosis to be made.
- (C) Children with tuberculosis are less likely to be smear positive than adults.
- (D) Rifampicin resistance can be reliably predicted using molecular methods to detect mutations in the *RpoB* gene.
- (E) Serology is of use in the diagnosis of tuberculosis in HIV positive patients.

Q5. Which of the statements are true:

- (A) *Mycobacterium bovis* is a recognised cause of primary pulmonary tuberculosis.
- (B) Those aged between 5 and 15 years old are at particular risk of tuberculosis.
- (C) HIV positive patients, once infected with tuberculosis, are at high risk of reinfection as well as reactivation.
- (D) Tuberculosis is expected to cause 30% of the expected AIDS related deaths in 1999.
- (E) In babies infected with HIV it is safe to give BCG vaccination.

Q6. In the year 1999 what percentage of the expected 2.5 million AIDS related deaths are estimated to be due to tuberculosis?

- (A) 10%
- (B) 30%
- (C) 50%
- (D) 70%
- (E) 90%

Q7. The overall annual risk of developing active tuberculosis infection in persons co-infected with the tubercle bacillus and HIV, compared with persons not infected by HIV, is increased by about:

- (A) 10 times
- (B) 20 times
- (C) 30 times
- (D) 40 times
- (E) 50 times

Q8. The region currently most affected by HIV and tuberculosis co-infection (the "cursed duet") is:

- (A) South East Asia
- (B) North Africa
- (C) Sub-Saharan Africa
- (D) USA
- (E) Europe

Q9. Which ONE of the following statements is false?

- (A) The standard WHO recommended anti-tuberculosis treatment is six months with rifampicin, isoniazid, pyrazinamide, and ethambutol/streptomycin.
- (B) HIV positive patients are less likely than non-HIV infected patients to complete the course of antituberculosis treatment.
- (C) Side effects of antituberculosis treatment are comparatively more common in HIV infected patients with tuberculosis.
- (D) Protease inhibitors and rifampicin rarely interact.
- (E) Drug resistant tuberculosis is by definition resistant to isoniazid and rifampicin.

Answers to multiple choice questions:

Q1:

- (A) False. The risk is much greater—being in the region of 20 times greater.
- (B) False. There is a roughly equal prevalence among the sexes with heterosexual sex being the commonest mode of transmission.
- (C) True. The commonest is malaria.
- (D) False. HIV infected patients with active pulmonary tuberculosis experience necrotising rather than granulomatous lung lesions that are not walled off by fibrous changes as in tuberculosis in non-HIV patients. This leaves the patient more prone to local invasion and disseminated disease throughout the body (cryptogenic disseminated tuberculosis).
- (E) False. Mortality is higher in those with HIV.

Q2:

- (A) True. Although the extent of induration is not related to CD4 count.
- (B) False. Between one third and one half of cases will be blood culture positive.
- (C) True. Pericarditis is the second commonest extrapulmonary manifestation after asymmetrical lymphadenopathy.
- (D) False. Central nervous system involvement is actually quite rare in those African patients with HIV and disseminated tuberculosis.
- (E) False. Severe wasting in Africans with HIV known as “slim disease” is thought to be associated with tuberculosis.

Q3:

- (A) False. Neuropathy is a side effect seen with isoniazid not ethambutol.
- (B) False. Survival in HIV positive patients with active tuberculosis is not affected by increasing the length of course of treatment.
- (C) False. Rifampicin is an enzyme inducer—not inhibitor.
- (D) True.
- (E) True.

Q4:

- (A) False. HIV positive patients with active tuberculosis are less likely to be smear positive.
- (B) False. Distinction between tuberculosis and other mycobacterial species (for example, *M. avium intracellulare*) cannot reliably be made on microscopy. The gold standard remains culture of the organism. Molecular methods can also be used.
- (C) True.
- (D) True.
- (E) False. Serology lacks both specificity and sensitivity especially in HIV positive patients.

Q5:

- (A) False. *M. bovis* causes primary infection in the pharynx or intestine (via drinking infected milk) rather than the lung. Although isolated institutionalised outbreaks have been reported among HIV infected patients there is no firm evidence that the spread was via primary lung infection.
- (B) False. Those within this age group have a relative protection against infection with tuberculosis—the “golden age group”.
- (C) True.
- (D) True.
- (E) False. There is an increased incidence of infectious complications with use of this live attenuated vaccine.

Q6:

- (B) True 30% (WHO estimates).

Q7:

- (B) True 20 times.

Q8:

- (C) True. While many regions are affected, sub-Saharan Africa appears to bear the brunt of the cursed duet of tuberculosis and HIV.

Q9:

- (D) True. Rifampicin induces enzymes in the cytochrome P-450 system and leads to interactions between these drugs.